An update on the diagnosis and management of hereditary angioedema with abnormal C1 inhibitor

Journal of Drugs in Dermatology

Volumn 14, Issue 2, 2015, Pages 151-157

  Davis Lorton, Mark ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIFIBRINOLYTIC AGENT; BRADYKININ B2 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; KALLIKREIN INHIBITOR;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ARTICLE; DELAYED DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; FACE EDEMA; HEALTH CARE COST; HUMAN; PATHOPHYSIOLOGY; PROPHYLAXIS; QUALITY OF LIFE; RASH; SCREENING TEST; URTICARIA; ANIMAL; GENETICS; HEREDITARY ANGIOEDEMA TYPES I AND II;

ANIMALS; COMPLEMENT C1 INHIBITOR PROTEIN; DELAYED DIAGNOSIS; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; QUALITY OF LIFE;

EID: 84922444055     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Cicardi M, Bork K, Caballero T., et al, on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012; 67:147-157.
2. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008; 359:1027-1036.
3. Davis AE III. The pathophysiology of hereditary angioedema. Clin Immunol. 2005; 114:3-9.
4. Zuraw BL, Bork K, Binkley K.E., et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012; 33:S145-S156.
5. Bork K, Meng G, Staubach P., Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006; 119:267-274.
6. Bowen T, Cicardi M, Farkas H., et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010; 6:24.
7. Zuraw BL, Banerji A, Bernstein J.A., et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol: In Practice. 2013; 1:458-467.
8. Lumry WR. Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema. Am J Manag Care. 2013; 19(7 suppl):S103-S110.
9. Zanichelli A, Magerl M, Longhurst H., et al. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin Immunol. 2013; 9:29.
10. Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med. 2003; 114:294-298.
11. Maurer M, Parish LC The dermatology view of hereditary angio-oedema: practical diagnostic and management considerations. J Eur Acad Dermatol Venereol. 2013; 27:133-141.
12. Berinert [package insert]. Kankakee, IL: CSL Behring LLC; 2011.
13. Cinryze [package insert]. Exton, PA: Viro Pharma Bioglogicso, Inc.; 2014.
14. Firazyr [package insert]. Lexington, MA: Shire Orphan Therapies, Inc.; 2011.
15. Gower RG, Busse PJ, Aygören-Pürsün E, et al. Hereditary angioedema caused by C1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. WAO Journal. 2011; 4(suppl):S9-S21.
16. Kalbitor [package insert]. Burlington, MA: Dyax Corp.; 2012.
17. Ruconest [summary of product characteristics]. Leiden, The Netherlands: Pharming Group N.V.; 2010.
18. Craig TJ, Bewtra AK, Bahna S.L., et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks: final results of the I.M.P.A.C.T2 study. Allergy. 2011; 66:1604-1611.
19. Craig TJ, Levy RJ, Wasserman R.L., et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124:801-808.
20. 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011; 107:529-537
21. Riedl M, Campion M, Horn P.T., Pullman WE. Response time for ecallantide treatment of acute hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2010; 105:430-436.
22. Zuraw BL, Busse PJ, White M, et al Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010; 363:513-522.
23. Zuraw B, Cicardi M, Levy R.J., et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010; 126:821-827
24. Wasserman RL, Levy RJ, Bewtra A.K., et al. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2011; 106:62-68.
25. Bork K, Meng G, Staubach P Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005; 45:1774-1784.
26. Riedl MA, Hurewitz DS, Levy R, et al Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. Ann Allergy Asthma Immunol. 2012; 108:49-53.
27. Lumry W, Manning ME, Hurewitz D.S., et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr. 2013; 162:1017-1022.
28. Baker JW, Craig TJ, Riedl M.A., et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy Asthma Proc. 2013; 34:162-169.
29. Cicardi M, Levy RJ, McNeil D.L., et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010; 363:523-531.
30. Levy RJ, Lumry WR, McNeil D.L., et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010; 104:523-529.
31. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010; 363:532-541.
32. Blohmé G. Treatment of hereditary angioneurotic oedema with tranexamic acid: a random double-blind cross-over study. Acta Med Scand. 1972; 192:293-298.
33. Frank MM, Sergent JS, Kane M.A., Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema - a double-blind study. N Engl J Med. 1972; 286:808-812.
34. Gelfand JA, Sherins RJ, Alling D.W., Frank MM. Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med. 1976; 295:1444-1448.
35. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008; 100:153-161.
36. Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin N Am. 2006; 26:653-668.
37. Lumry WR. Management and prevention of hereditary angioedema attacks. Am J Manag Care. 2013; 19(SUPPL. 7):S111-S118.
38. Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012; 125:938.e1-e7
39. Bernstein JA, Manning ME, Li H, et al Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2014; 2:77-84.
40. Grant JA, White MV, Li H.H., et al. Preprocedural administration of nanofilttered C1 esterase inhibitor to prevent hereditary angioede maattacks. Allergy Asthma proc. 2012; 33:348-353.
41. http://www.cinryze.com/hae-patient-assistance.aspx. Accessed August 22, 2014.
42. http://haea.org/about/patient-services/. Accessed August 22, 2014.
43. http://www.firazyr.com. Accessed August 22, 2014.
44. http://haehope.com/living-with-hae/resources.html.